Last reviewed · How we verify

NCT03700632

Part-time Patch Therapy for Treatment of Intermittent Exotropia

Status unknown NA Last updated 9 October 2018
What this trial tests

NA trial testing patch therapy in Intermittent Exotropia in 64 participants. Status unknown.

Timeline
1 November 2018
Primary endpoint
10 May 2020
10 November 2021

Quick facts

Lead sponsorTehran University of Medical Sciences
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposetreatment
Enrollment64
Start date1 November 2018
Primary completion10 May 2020
Estimated completion10 November 2021

Drugs / interventions tested

Conditions studied

Sponsor

Tehran University of Medical Sciences

Who can join

Adults 3 to 8, any sex, with Intermittent Exotropia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Intermittent exotropia is the most common type of exotropia in children. Treatment options are surgical and non surgical. Nonsurgical management include Correction of refractive errors, Active orthoptic treatments, Prisms and Occlusion therapy. Benefits of patch therapy are limiting suppression, reducing the frequency and amplitude of the deviation, changing the nature of the deviation (from constant to intermittent exotropia or from intermittent exotropia to exophoria), however, there is a concern that occlusion of the eyes may cause fusion failure and worsen deviation control. According to a few number of studies and controversy among the results of investigations, the investigators designed this randomized clinical trial study to determine the effect of partial patch therapy on the deviation control of children with intermittent exotropia.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. The influence of alternate part-time patching on control of intermittent exotropia: a randomized clinical trial.
    Akbari MR, Mehrpour M, Mirmohammadsadeghi A. · · 2021 · cited 10× · PMID 33415357 · DOI 10.1007/s00417-020-05065-0

Verify or expand the search:

Other Tehran University of Medical Sciences trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03700632.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing